SEARCH

SEARCH BY CITATION

References

  • Abbas N, Lucking CB, Ricard S, Durr A, Bonifati V, De MG, Bouley S, Vaughan JR, Gasser T, Marconi R, Broussolle E, Brefel-Courbon C, Harhangi BS, Oostra BA, Fabrizio E, Bohme GA, Pradier L, Wood NW, Filla A, Meco G, Denefle P, Agid Y, Brice A. 1999. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum Mol Genet 8:567574.
  • Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. 2000. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:239252.
  • Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW. 2003. The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol 54:283286.
  • Abou-Sleiman PM, Muqit MM, McDonald NQ, Yang YX, Gandhi S, Healy DG, Harvey K, Harvey RJ, Deas E, Bhatia K, Quinn N, Lees A, Latchman DS, Wood NW. 2006. A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol 60:414419.
  • Adel S, Djarmati A, Kabakci K, Pichler I, Eskelson C, Lohnau T, Kock N, Hagenah J, Hedrich K, Schwinger E, Kramer PL, Pramstaller PP, Klein C. 2006. Co-occurrence of restless legs syndrome and Parkin mutations in two families. Mov Disord 21:258263.
  • Aguiar PC, Lessa PS, GodeiroJr C, Barsottini O, Felicio AC, Borges V, Silva SM, Saba RA, Ferraz HB, Moreira-Filho CA, Andrade LA. 2008. Genetic and environmental findings in early-onset Parkinson's disease Brazilian patients. Mov Disord 23:12281233.
  • Ahn TB, Kim SY, Kim JY, Park SS, Lee DS, Min HJ, Kim YK, Kim SE, Kim JM, Kim HJ, Cho J, Jeon BS. 2008. alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 70:4349.
  • Alvarez V, Guisasola LM, Moreira VG, Lahoz CH, Coto E. 2001. Early-onset Parkinson's disease associated with a new parkin mutation in a Spanish family. Neurosci Lett 313:108110.
  • An XK, Peng R, Li T, Burgunder JM, Wu Y, Chen WJ, Zhang JH, Wang YC, Xu YM, Gou YR, Yuan GG, Zhang ZJ. 2008. LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. Eur J Neurol 15:301305.
  • Anand VS, Reichling LJ, Lipinski K, Stochaj W, Duan W, Kelleher K, Pungaliya P, Brown EL, Reinhart PH, Somberg R, Hirst WD, Riddle SM, Braithwaite SP. 2009. Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays. FEBS J 276:466478.
  • Annesi F, Rocca EF, Ciro Candiano I, Carrideo S, Tarantino P, Provenzano G, Civitelli D, De Marco EV, Quattrone A, Annesi G. 2007. Novel human pathological mutations. Gene symbol: PARK2. Disease: Parkinson's disease. Hum Genet 122:415.
  • Annesi G, Savettieri G, Pugliese P, D'Amelio M, Tarantino P, Ragonese P, La Bella V, Piccoli T, Civitelli D, Annesi F, Fierro B, Piccoli F, Arabia G, Caracciolo M, Ciro Candiano I, Quattrone A. 2005. DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral sclerosis complex. Ann Neurol 58:803807.
  • Arias VA, Sleegers K, Dekker MC, van Gool WA, van Swieten JC, Aulchenko YS, Oostra BA, van Duijn CM. 2004. A deletion in DJ-1 and the risk of dementia—a population-based survey. Neurosci Lett 372:196199.
  • Athanassiadou A, Voutsinas G, Psiouri L, Leroy E, Polymeropoulos MH, Ilias A, Maniatis GM, Papapetropoulos T. 1999. Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am J Hum Genet 65:555558.
  • Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T. 1998. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152:879884.
  • Bardien S, Keyser R, Yako Y, Lombard D, Carr J. 2009. Molecular analysis of the parkin gene in South African patients diagnosed with Parkinson's disease. Parkinsonism Relat Disord 15:116121.
  • Bayrakli F, Bilguvar K, Mason CE, DiLuna ML, Bayri Y, Gungor L, Terzi M, Mane SM, Lifton RP, State MW, Gunel M. 2007. Rapid identification of disease-causing mutations using copy number analysis within linkage intervals. Hum Mutat 28:12361240.
  • Bentivoglio AR, Cortelli P, Valente EM, Ialongo T, Ferraris A, Elia A, Montagna P, Albanese A. 2001. Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. Mov Disord 16:9991006.
  • Berg D, Schweitzer K, Leitner P, Zimprich A, Lichtner P, Belcredi P, Brussel T, Schulte C, Maass S, Nagele T. 2005. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain 128:30003011.
  • Bertoli-Avella AM, Giroud-Benitez JL, Akyol A, Barbosa E, Schaap O, van der Linde HC, Martignoni E, Lopiano L, Lamberti P, Fincati E. 2005. Novel parkin mutations detected in patients with early-onset Parkinson's disease. Mov Disord 20:424431.
  • Biswas A, Gupta A, Naiya T, Das G, Neogi R, Datta S, Mukherjee S, Das SK, Ray K, Ray J. 2006. Molecular pathogenesis of Parkinson's disease: identification of mutations in the Parkin gene in Indian patients. Parkinsonism Relat Disord 12:420426.
  • Bodner RA, Housman DE, Kazantsev AG. 2006. New directions for neurodegenerative disease therapy: using chemical compounds to boost the formation of mutant protein inclusions. Cell Cycle 5:14771480.
  • Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P. 2003. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256259.
  • Bonifati V, Rohe CF, Breedveld GJ, Fabrizio E, De MM, Tassorelli C, Tavella A, Marconi R, Nicholl DJ, Chien HF, Fincati E, Abbruzzese G, Marini P. 2005. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65:8795.
  • Bostantjopoulou S, Katsarou Z, Papadimitriou A, Veletza V, Hatzigeorgiou G, Lees A. 2001. Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. Mov Disord 16:10071013.
  • Bras J, Guerreiro R, Ribeiro M, Morgadinho A, Januario C, Dias M, Calado A, Semedo C, Oliveira C, Hardy J, Singleton A. 2008. Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. BMC Neurol 8:1.
  • Brighina L, Frigerio R, Schneider NK, Lesnick TG, de Andrade M, Cunningham JM, Farrer MJ, Lincoln SJ, Checkoway H, Rocca WA, Maraganore DM. 2008. Alpha-synuclein, pesticides, and Parkinson disease: a case–control study. Neurology 70:14611469.
  • Brooks J, Ding J, Simon-Sanchez J, Paisan-Ruiz C, Singleton AB, Scholz SW. 2009. Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available cases and control. J Med Genet 46:375381.
  • Bruggemann N, Mitterer M, Lanthaler AJ, Djarmati A, Hagenah J, Wiegers K, Winkler S, Pawlack H, Lohnau T, Pramstaller PP, Klein C, Lohmann K. 2009. Frequency of heterozygous Parkin mutations in healthy subjects: need for careful prospective follow-up examination of mutation carriers. Parkinsonism Relat Disord 15:425429.
  • Camargos ST, Dornas LO, Momeni P, Lees A, Hardy J, Singleton A, Cardoso F. 2009. Familial Parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations. Mov Disord 24:662666.
  • Carmine Belin A, Westerlund M, Sydow O, Lundstromer K, Hakansson A, Nissbrandt H, Olson L, Galter D. 2006. Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Mov Disord 21:17311734.
  • Cazeneuve C, San C, Ibrahim SA, Mukhtar MM, Kheir MM, Leguern E, Brice A, Salih MA. 2009. A new complex homozygous large rearrangement of the PINK1 gene in a Sudanese family with early onset Parkinson's disease. Neurogenetics 10:265270.
  • Chan DK, Mok V, Ng PW, Yeung J, Kwok JB, Fang ZM, Clarke R, Wong L, Schofield PR, Hattori N. 2008. PARK2 mutations and clinical features in a Chinese population with early-onset Parkinson's disease. J Neural Transm 115:715719.
  • Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A. 2004. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364:11671169.
  • Chaudhary S, Behari M, Dihana M, Swaminath PV, Govindappa ST, Jayaram S, Goyal V, Maitra A, Muthane UB, Juyal RC, Thelma BK. 2006. Parkin mutations in familial and sporadic Parkinson's disease among Indians. Parkinsonism Relat Disord 12:239245.
  • Chen R, Gosavi NS, Langston JW, Chan P. 2003. Parkin mutations are rare in patients with young-onset parkinsonism in a US population. Parkinsonism Relat Disord 9:309312.
  • Chen-Plotkin AS, Yuan W, Anderson C, McCarty WE, Hurtig HI, Clark CM, Miller BL, Lee VM, Trojanowski JQ, Grossman M, Van Deerlin V. 2008. Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 70:521527.
  • Chishti MA, Bohlega S, Ahmed M, Loualich A, Carroll P, Sato C, St. George-Hyslop P, Westaway D, Rogaeva E. 2006. T313M PINK1 mutation in an extended highly consanguineous Saudi family with early-onset Parkinson disease. Arch Neurol 63:14831485.
  • Choi JM, Woo MS, Ma HI, Kang SY, Sung YH, Yong SW, Chung SJ, Kim JS, Shin HW, Lyoo CH, Lee PH, Baik JS, Kim SJ, Park MY, Sohn YH, Kim JH, Kim JW, Lee MS, Lee MC, Kim DH, Kim YJ. 2008. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics 9:263269.
  • Chung SJ, Park HK, Ki CS, Kim MJ, Lee MC. 2008. Marked diurnal fluctuation and rest benefit in a patient with parkin mutation. Mov Disord 23:624626.
  • Ciro Candiano I, Annesi F, Rocca EF, Carrideo S, Tarantino P, Provenzano G, Civitelli D, De Marco EV, Quattrone A, Annesi G. 2007. Novel human pathological mutations. Gene symbol: PARK2. Disease: Parkinson's disease. Hum Genet 122:416.
  • Clarimon J, Johnson J, Dogu O, Horta W, Khan N, Lees AJ, Hardy J, Singleton A. 2005. Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 133B:120123.
  • Clarimon J, Pagonabarraga J, Paisan-Ruiz C, Campolongo A, Pascual-Sedano B, Marti-Masso JF, Singleton AB, Kulisevsky J. 2008. Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening. Mov Disord 23:518523.
  • Clark LN, Afridi S, Karlins E, Wang Y, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K. 2006. Case–control study of the parkin gene in early-onset Parkinson disease. Arch Neurol 63:548552.
  • Clark LN, Afridi S, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Singleton A, Wavrant De-Vrieze F, Hardy J, Mayeux R, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K. 2004. Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutations. Mov Disord 19:796800.
  • Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, LansburyJr PT. 2000. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97:571576.
  • Cookson MR. 2005. The biochemistry of Parkinson's disease. Annu Rev Biochem 74:2952.
  • Criscuolo C, Volpe G, De Rosa A, Varrone A, Marongiu R, Mancini P, Salvatore E, Dallapiccola B, Filla A, Valente EM, De Marco G. 2006. PINK1 homozygous W437X mutation in a patient with apparent dominant transmission of parkinsonism. Mov Disord 21:12651267.
  • Dachsel JC, Mata IF, Ross OA, Taylor JP, Lincoln SJ, Hinkle KM, Huerta C, Ribacoba R, Blazquez M, Alvarez V, Farrer MJ. 2006. Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2. Neurosci Lett 410:8084.
  • Dachsel JC, Ross OA, Mata IF, Kachergus J, Toft M, Cannon A, Baker M, Adamson J, Hutton M, Dickson DW, Farrer MJ. 2007. Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. Acta Neuropathol 113:601606.
  • Davidson WS, Jonas A, Clayton DF, George JM. 1998. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273:94439449.
  • Deng H, Dodson MW, Huang H, Guo M. 2008a. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci USA 105:1450314508.
  • Deng H, Le W, Shahed J, Xie W, Jankovic J. 2008b. Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families. Neurosci Lett 430:1822.
  • Deng H, Le WD, Hunter CB, Mejia N, Xie WJ, Jankovic J. 2007. A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. Arch Neurol 64:421424.
  • Di Fonzo A, Dekker MC, Montagna P, Baruzzi A, Yonova EH, Correia GL, Szczerbinska A, Zhao T, Dubbel-Hulsman LO, Wouters CH, de Graaff E, Oyen WJ, Simons EJ, Breedveld GJ, Oostra BA, Horstink MW, Bonifati V. 2009. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 72:240245.
  • Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, Goldwurm S, Breedveld G, Sampaio C, Meco G, Barbosa E, Oostra BA, Bonifati V. 2005. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365:412415.
  • Di Fonzo A, Tassorelli C, De MM, Chien HF, Ferreira J, Rohe CF, Riboldazzi G, Antonini A, Albani G, Mauro A, Marconi R, Abbruzzese G, Lopiano L, Fincati E, Guidi M, Marini P, Stocchi F, Onofrj M, Toni V, Tinazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leitner P, Uitti RJ, Wszolek ZK, Gasser T, Simons EJ, Breedveld GJ, Goldwurm S, Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Oostra BA, Bonifati V. 2006a. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 14:322331.
  • Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, Rohe CF, Chang HC, Chen RS, Weng YH, Vanacore N, Breedveld GJ, Oostra BA, Bonifati V. 2006b. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7:133138.
  • Djarmati A, Hedrich K, Svetel M, Lohnau T, Schwinger E, Romac S, Pramstaller PP, Kostic V, Klein C. 2006. Heterozygous PINK1 mutations: a susceptibility factor for Parkinson disease? Mov Disord 21:15261530.
  • Djarmati A, Hedrich K, Svetel M, Schafer N, Juric V, Vukosavic S, Hering R, Riess O, Romac S, Klein C, Kostic V. 2004. Detection of Parkin (PARK2) and DJ1 (PARK7) mutations in early-onset Parkinson disease: Parkin mutation frequency depends on ethnic origin of patients. Hum Mutat 23:525.
  • Ephraty L, Porat O, Israeli D, Cohen OS, Tunkel O, Yael S, Hatano Y, Hattori N, Hassin-Baer S. 2007. Neuropsychiatric and cognitive features in autosomal-recessive early parkinsonism due to PINK1 mutations. Mov Disord 22:566569.
  • Exner N, Treske B, Paquet D, Holmstrom K, Schiesling C, Gispert S, Carballo-Carbajal I, Berg D, Hoepken HH, Gasser T, Kruger R, Winklhofer KF, Vogel F, Reichert AS, Auburger G, Kahle PJ, Schmid B, Haass C. 2007. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 27:1241312418.
  • Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D, Forno L, Gwinn-Hardy K, Petrucelli L, Hussey J, Singleton A, Tanner C, Hardy J, Langston JW. 2001a. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 50:293300.
  • Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D, Langston JW. 2004. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 55:174179.
  • Farrer M, Maraganore DM, Lockhart P, Singleton A, Lesnick TG, de Andrade M, West A, de Silva R, Hardy J, Hernandez D. 2001b. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 10:18471851.
  • Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, Strain KJ, Maraganore DM. 2005. LRRK2 mutations in Parkinson disease. Neurology 65:738740.
  • Farrer MJ, Stone JT, Lin CH, Dachsel JC, Hulihan MM, Haugarvoll K, Ross OA, Wu RM. 2007. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat Disord 13:8992.
  • Ferreira JJ, Guedes LC, Rosa MM, Coelho M, van DM, Schweiger D, Di FA, Oostra BA, Sampaio C, Bonifati V. 2007. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. Mov Disord 22:11941201.
  • Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Marder K, Conneally PM, Nichols WC. 2003. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 60:796801.
  • Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schule B, Langston JW, Middleton FA, Ross OA, Hulihan M, Gasser T, Farrer MJ. 2007. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68:916922.
  • Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. 2002. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1. Ann Neurol 51:296301.
  • Funayama M, Li Y, Tsoi TH, Lam CW, Ohi T, Yazawa S, Uyama E, Djaldetti R, Melamed E, Yoshino H, Imamichi Y, Takashima H, Nishioka K, Sato K, Tomiyama H, Kubo S, Mizuno Y, Hattori N. 2008. Familial Parkinsonism with digenic parkin and PINK1 mutations. Mov Disord 23:14611465.
  • Fung HC, Chen CM, Hardy J, Singleton AB, Lee-Chen GJ, Wu YR. 2006a. Analysis of the PINK1 gene in a cohort of patients with sporadic early-onset parkinsonism in Taiwan. Neurosci Lett 394:3336.
  • Fung HC, Chen CM, Hardy J, Singleton AB, Wu YR. 2006b. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol 6:47.
  • Gaig C, Ezquerra M, Marti MJ, Munoz E, Valldeoriola F, Tolosa E. 2006. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 63:377382.
  • Gaig C, Ezquerra M, Marti MJ, Valldeoriola F, Munoz E, Llado A, Rey MJ, Cardozo A, Molinuevo JL, Tolosa E. 2008. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J Neurol Sci 270:9498.
  • Gaig C, Marti MJ, Ezquerra M, Rey MJ, Cardozo A, Tolosa E. 2007. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J Neurol Neurosurg Psychiatry 78:626628.
  • Gandhi S, Wood-Kaczmar A, Yao Z, Plun-Favreau H, Deas E, Klupsch K, Downward J, Latchman DS, Tabrizi SJ, Wood NW, Duchen MR, Abramov AY. 2009. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell 33:627638.
  • Gao L, Gomez-Garre P, az-Corrales FJ, Carrillo F, Carballo M, Palomino A, az-Martin J, Mejias R, Vime PJ, Lopez-Barneo J, Mir P. 2009. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain. Eur J Neurol.
  • Gelmetti V, Ferraris A, Brusa L, Romano F, Lombardi F, Barzaghi C, Stanzione P, Garavaglia B, Dallapiccola B, Valente EM. 2008. Late onset sporadic Parkinson's disease caused by PINK1 mutations: clinical and functional study. Mov Disord 23:881885.
  • Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van DV. 2006. Biochemical and pathological characterization of Lrrk2. Ann Neurol 59:315322.
  • Gilks WP, bou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, Lynch J, Healy DG, Holton JL, Revesz T, Wood NW. 2005. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365:415416.
  • Giordana MT, D'Agostino C, Albani G, Mauro A, Di FA, Antonini A, Bonifati V. 2007. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation. Mov Disord 22:275278.
  • Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M. 2006. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15:223232.
  • Godeiro-Junior C, de Carvalho-Aguiar PM, Felicio AC, Barsottini OG, Silva SM, Borges V, Andrade LA, Ferraz HB. 2009. PINK1 mutations in a Brazilian cohort of early-onset Parkinson's disease patients. Mov Disord.
  • Goldwurm S, Di Fonzo A, Simons EJ, Rohe CF, Zini M, Canesi M, Tesei S, Zecchinelli A, Antonini A, Mariani C, Meucci N, Sacilotto G, Sironi F, Salani G, Ferreira J, Chien HF, Fabrizio E, Vanacore N, Dalla LA, Stocchi F, Diroma C, Lamberti P, Sampaio C, Meco G, Barbosa E, Bertoli-Avella AM, Breedveld GJ, Oostra BA, Pezzoli G, Bonifati V. 2005. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 42:e65.
  • Gonzalez-Fernandez MC, Lezcano E, Ross OA, Gomez-Esteban JC, Gomez-Busto F, Velasco F, varez-Alvarez M, Rodriguez-Martinez MB, Ciordia R, Zarranz JJ, Farrer MJ, Mata IF, de Pancorbo MM. 2007. Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. Parkinsonism Relat Disord 13:509515.
  • Gorostidi A, Ruiz-Martinez J, de Munain AL, Alzualde A, Masso JF. 2009. LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 10:157159.
  • Gosal D, Lynch T, Ross OA, Haugarvoll K, Farrer MJ, Gibson JM. 2007. Global distribution and reduced penetrance: Lrrk2 R1441C in an Irish Parkinson's disease kindred. Mov Disord 22:291292.
  • Gotthardt K, Weyand M, Kortholt A, Van Haastert PJ, Wittinghofer A. 2008. Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J 27:2352.
  • Gouider-Khouja N, Larnaout A, Amouri R, Sfar S, Belal S, Ben HC, Ben HM, Hattori N, Mizuno Y, Hentati F. 2003. Autosomal recessive parkinsonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study. Parkinsonism.Relat Disord 9:247251.
  • Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. 2003. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 100:40784083.
  • Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, Cookson MR. 2006. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23:329341.
  • Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniels V, Lewis P, Jain S, Ding J, Syed A, Thomas KJ, Baekelandt V, Cookson MR. 2008. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 283:1690616914.
  • Guo JF, Xiao B, Liao B, Zhang XW, Nie LL, Zhang YH, Shen L, Jiang H, Xia K, Pan Q, Yan XX, Tang BS. 2008. Mutation analysis of Parkin, PINK1, DJ-1 and ATP13A2 genes in Chinese patients with autosomal recessive early-onset Parkinsonism. Mov Disord 23:20742079.
  • Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, Chen SG. 2007. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313:36583670.
  • Gwinn-Hardy K, Mehta ND, Farrer M, Maraganore D, Muenter M, Yen SH, Hardy J, Dickson DW. 2000. Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol 99:663672.
  • Hadjigeorgiou GM, Xiromerisiou G, Gourbali V, Aggelakis K, Scarmeas N, Papadimitriou A, Singleton A. 2006. Association of alpha-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onset. Mov Disord 21:534539.
  • Hague S, Rogaeva E, Hernandez D, Gulick C, Singleton A, Hanson M, Johnson J, Weiser R, Gallardo M, Ravina B, Gwinn-Hardy K, Crawley A, PH SG-H, Lang AE, Heutink P, Bonifati V, Hardy J, Singleton A. 2003. Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol 54:271274.
  • Harbo HF, Finsterer J, Baets J, Van BC, Di DS, Fontaine B, De JP, Lossos A, Lynch T, Mariotti C, Schols L, Spinazzola A, Szolnoki Z, Tabrizi SJ, Tallaksen C, Zeviani M, Burgunder JM, Gasser T. 2009. EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias. Eur J Neurol 16:777785.
  • Hatano Y, Li Y, Sato K, Asakawa S, Yamamura Y, Tomiyama H, Yoshino H, Asahina M, Kobayashi S, Hassin-Baer S, Lu CS, Ng AR, Rosales RL, Shimizu N, Toda T, Mizuno Y, Hattori N. 2004. Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol 56:424427.
  • Hattori N, Kitada T, Matsumine H, Asakawa S, Yamamura Y, Yoshino H, Kobayashi T, Yokochi M, Wang M, Yoritaka A, Kondo T, Kuzuhara S, aNakamura S, Shimizu N, Mizuno Y. 1998a. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol 44:935941.
  • Hattori N, Matsumine H, Asakawa S, Kitada T, Yoshino H, Elibol B, Brookes AJ, Yamamura Y, Kobayashi T, Wang M, Yoritaka A, Minoshima S, Shimizu N, Mizuno Y. 1998b. Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene. Biochem Biophys Res Commun 249:754758.
  • Haubenberger D, Bonelli S, Hotzy C, Leitner P, Lichtner P, Samal D, Katzenschlager R, Djamshidian A, Brucke T, Steffelbauer M, Bancher C, Grossmann J, Ransmayr G, Strom TM, Meitinger T, Gasser T, Auff E, Zimprich A. 2007. A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease. Mov Disord 22:16401643.
  • Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK. 2008. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70:14561460.
  • Hayashi S, Wakabayashi K, Ishikawa A, Nagai H, Saito M, Maruyama M, Takahashi T, Ozawa T, Tsuji S, Takahashi H. 2000. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 15:884888.
  • Healy DG, bou-Sleiman PM, Gibson JM, Ross OA, Jain S, Gandhi S, Gosal D, Muqit MM, Wood NW, Lynch T. 2004. PINK1 (PARK6) associated Parkinson disease in Ireland. Neurology 63:14861488.
  • Hedrich K, Djarmati A, Schafer N, Hering R, Wellenbrock C, Weiss PH, Hilker R, Vieregge P, Ozelius LJ, Heutink P, Bonifati V, Schwinger E, Lang AE, Noth J, Bressman SB, Pramstaller PP, Riess O, Klein C. 2004a. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 62:389394.
  • Hedrich K, Eskelson C, Wilmot B, Marder K, Harris J, Garrels J, Meija-Santana H, Vieregge P, Jacobs H, Bressman SB, Lang AE, Kann M, Abbruzzese G, Martinelli P, Schwinger E, Ozelius LJ, Pramstaller PP, Klein C, Kramer P. 2004b. Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord 19:11461157.
  • Hedrich K, Hagenah J, Djarmati A, Hiller A, Lohnau T, Lasek K, Grunewald A, Hilker R, Steinlechner S, Boston H, Kock N, Schneider-Gold C, Kress W, Siebner H, Binkofski F, Lencer R, Munchau A, Klein C. 2006a. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? Arch Neurol 63:833838.
  • Hedrich K, Kann M, Lanthaler AJ, Dalski A, Eskelson C, Landt O, Schwinger E, Vieregge P, Lang AE, Breakefield XO, Ozelius LJ, Pramstaller PP, Klein C. 2001. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum Mol Genet 10:16491656.
  • Hedrich K, Marder K, Harris J, Kann M, Lynch T, Meija-Santana H, Pramstaller PP, Schwinger E, Bressman SB, Fahn S, Klein C. 2002. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology 58:12391246.
  • Hedrich K, Winkler S, Hagenah J, Kabakci K, Kasten M, Schwinger E, Volkmann J, Pramstaller PP, Kostic V, Vieregge P, Klein C. 2006b. Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease. Mov Disord 21:15061510.
  • Hering R, Strauss KM, Tao X, Bauer A, Woitalla D, Mietz EM, Petrovic S, Bauer P, Schaible W, Muller T, Schols L, Klein C, Berg D, Meyer PT, Schulz JB, Wollnik B, Tong L, Kruger R, Riess O. 2004. Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum Mutat 24:321329.
  • Hernandez D, Paisan RC, Crawley A, Malkani R, Werner J, Gwinn-Hardy K, Dickson D, Wavrant DF, Hardy J, Singleton A. 2005. The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci Lett 389:137139.
  • Hertz JM, Ostergaard K, Juncker I, Pedersen S, Romstad A, Moller LB, Guttler F, Dupont E. 2006. Low frequency of Parkin, Tyrosine Hydroxylase, and GTP Cyclohydrolase I gene mutations in a Danish population of early-onset Parkinson's Disease. Eur J Neurol 13:385390.
  • Hoenicka J, Vidal L, Morales B, Ampuero I, Jimenez-Jimenez FJ, Berciano J, del ST, Jimenez A, Ruiz PG, de Yebenes JG. 2002. Molecular findings in familial Parkinson disease in Spain. Arch Neurol 59:966970.
  • Huang Y, Halliday GM, Vandebona H, Mellick GD, Mastaglia F, Stevens J, Kwok J, Garlepp M, Silburn PA, Horne MK, Kotschet K, Venn A, Rowe DB, Rubio JP, Sue CM. 2007. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Mov Disord 22:982989.
  • Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A. 2004. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364:11691171.
  • Ibanez P, Lesage S, Janin S, Lohmann E, Durif F, Destee A, Bonnet AM, Brefel-Courbon C, Heath S, Zelenika D, Agid Y, Durr A, Brice A. 2009. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol 66:102108.
  • Ibanez P, Lesage S, Lohmann E, Thobois S, De MG, Borg M, Agid Y, Durr A, Brice A. 2006. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 129:686694.
  • Ikeuchi T, Kakita A, Shiga A, Kasuga K, Kaneko H, Tan CF, Idezuka J, Wakabayashi K, Onodera O, Iwatsubo T, Nishizawa M, Takahashi H, Ishikawa A. 2008. Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch Neurol 65:514519.
  • Illarioshkin SN, Periquet M, Rawal N, Lucking CB, Zagorovskaya TB, Slominsky PA, Miloserdova OV, Markova ED, Limborska SA, Ivanova-Smolenskaya IA, Brice A. 2003. Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism. Mov Disord 18:914919.
  • Illarioshkin SN, Shadrina MI, Slominsky PA, Bespalova EV, Zagorovskaya TB, Bagyeva GK, Markova ED, Limborska SA, Ivanova-Smolenskaya IA. 2007. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia. Eur J Neurol 14:413417.
  • Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B. 2008. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 27:24322443.
  • Imai Y, Soda M, Takahashi R. 2000. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 275:3566135664.
  • Izumi Y, Morino H, Oda M, Maruyama H, Udaka F, Kameyama M, Nakamura S, Kawakami H. 2001. Genetic studies in Parkinson's disease with an alpha-synuclein/NACP gene polymorphism in Japan. Neurosci Lett 300:125127.
  • Johnson J, Paisan-Ruiz C, Lopez G, Crews C, Britton A, Malkani R, Evans EW, Inerney-Leo A, Jain S, Nussbaum RL, Foote KD, Mandel RJ, Crawley A, Reimsnider S, Fernandez HH, Okun MS, Gwinn-Hardy K, Singleton AB. 2007. Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation. Neurodegener Dis 4:386391.
  • Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M. 2005. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76:672680.
  • Kann M, Jacobs H, Mohrmann K, Schumacher K, Hedrich K, Garrels J, Wiegers K, Schwinger E, Pramstaller PP, Breakefield XO, Ozelius LJ, Vieregge P, Klein C. 2002. Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. Ann Neurol 51:621625.
  • Kay DM, Factor SA, Samii A, Higgins DS, Griffith A, Roberts JW, Leis BC, Nutt JG, Montimurro JS, Keefe RG, Atkins AJ, Yearout D, Zabetian CP, Payami H. 2008. Genetic association between alpha-synuclein and idiopathic Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 147B:12221230.
  • Kay DM, Kramer P, Higgins D, Zabetian CP, Payami H. 2005. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Mov Disord 20:10771078.
  • Kay DM, Moran D, Moses L, Poorkaj P, Zabetian CP, Nutt J, Factor SA, Yu CE, Montimurro JS, Keefe RG, Schellenberg GD, Payami H. 2007. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann Neurol 61:4754.
  • Kazantsev AG, Kolchinsky AM. 2008. Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease. Arch Neurol 65:15771581.
  • Khan NL, Horta W, Eunson L, Graham E, Johnson JO, Chang S, Davis M, Singleton A, Wood NW, Lees AJ. 2005a. Parkin disease in a Brazilian kindred: manifesting heterozygotes and clinical follow-up over 10 years. Mov Disord 20:479484.
  • Khan NL, Jain S, Lynch JM, Pavese N, bou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW. 2005b. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128:27862796.
  • Ki CS, Stavrou EF, Davanos N, Lee WY, Chung EJ, Kim JY, Athanassiadou A. 2007. The Ala53Thr mutation in the alpha-synuclein gene in a Korean family with Parkinson disease. Clin Genet 71:471473.
  • Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605608.
  • Klein C, Djarmati A, Hedrich K, Schafer N, Scaglione C, Marchese R, Kock N, Schule B, Hiller A, Lohnau T, Winkler S, Wiegers K, Hering R, Bauer P, Riess O, Abbruzzese G, Martinelli P, Pramstaller PP. 2005. PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. Eur J Hum Genet 13:10861093.
  • Klein C, Pramstaller PP, Kis B, Page CC, Kann M, Leung J, Woodward H, Castellan CC, Scherer M, Vieregge P, Breakefield XO, Kramer PL, Ozelius LJ. 2000. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann Neurol 48:6571.
  • Kobayashi T, Wang M, Hattori N, Matsumine H, Kondo T, Mizuno Y. 2000. Exonic deletion mutations of the Parkin gene among sporadic patients with Parkinson's disease. Parkinsonism Relat Disord 6:129131.
  • Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18:106108.
  • Kumazawa R, Tomiyama H, Li Y, Imamichi Y, Funayama M, Yoshino H, Yokochi F, Fukusako T, Takehisa Y, Kashihara K, Kondo T, Elibol B, Bostantjopoulou S, Toda T, Takahashi H, Yoshii F, Mizuno Y, Hattori N. 2008. Mutation analysis of the PINK1 gene in 391 patients with Parkinson disease. Arch Neurol 65:802808.
  • Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Goldwurm S, Pezzoli G, Zini M, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Laramie JM, DeStefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. 2008. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med 6:32.
  • Lautier C, Goldwurm S, Durr A, Giovannone B, Tsiaras WG, Pezzoli G, Brice A, Smith RJ. 2008. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet 82:822833.
  • Lee MJ, Mata IF, Lin CH, Tzen KY, Lincoln SJ, Bounds R, Lockhart PJ, Hulihan MM, Farrer MJ, Wu RM. 2009. Genotype–phenotype correlates in Taiwanese patients with early-onset recessive Parkinsonism. Mov Disord 24:104108.
  • Leroy E, Anastasopoulos D, Konitsiotis S, Lavedan C, Polymeropoulos MH. 1998a. Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease. Hum Genet 103:424427.
  • Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH. 1998b. The ubiquitin pathway in Parkinson's disease. Nature 395:451452.
  • Lesage S, Condroyer C, Lannuzel A, Lohmann E, Troiano A, Tison F, Damier P, Thobois S, Ouvrard-Hernandez AM, Rivaud-Pechoux S, Brefel-Courbon C, Destee A, Tranchant C, Romana M, Leclere L, Durr A, Brice A. 2009. Molecular analyses of the LRRK2 gene in European and North-African autosomal dominant Parkinson's disease. J Med Genet 46:458464.
  • Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, Brice A. 2006. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 354:422423.
  • Lesage S, Janin S, Lohmann E, Leutenegger AL, Leclere L, Viallet F, Pollak P, Durif F, Thobois S, Layet V, Vidailhet M, Agid Y, Durr A, Brice A, Bonnet AM, Borg M, Broussolle E, Damier P, Destee A, Martinez M, Penet C, Rasco O, Tison F, Tranchan C, Verin M. 2007a. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. Arch Neurol 64:425430.
  • Lesage S, Lohmann E, Tison F, Durif F, Durr A, Brice A. 2008. Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. J Med Genet 45:4346.
  • Lesage S, Magali P, Lohmann E, Lacomblez L, Teive H, Janin S, Cousin PY, Durr A, Brice A. 2007b. Deletion of the parkin and PACRG gene promoter in early-onset parkinsonism. Hum Mutat 28:2732.
  • Leutenegger AL, Salih MA, Ibanez P, Mukhtar MM, Lesage S, Arabi A, Lohmann E, Durr A, Ahmed AE, Brice A. 2006. Juvenile-onset Parkinsonism as a result of the first mutation in the adenosine triphosphate orientation domain of PINK1. Arch Neurol 63:12571261.
  • Lev N, Ickowicz D, Barhum Y, Lev S, Melamed E, Offen D. 2009. DJ-1 protects against dopamine toxicity. J Neural Transm 116:151160.
  • Lewis PA, Greggio E, Beilina A, Jain S, Baker A, Cookson MR. 2007. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 357:668671.
  • Li X, Kitami T, Wang M, Mizuno Y, Hattori N. 2005a. Geographic and ethnic differences in frequencies of two polymorphisms (D/N394 and L/I272) of the parkin gene in sporadic Parkinson's disease. Parkinsonism.Relat Disord 11:485491.
  • Li X, Tan YC, Poulose S, Olanow CW, Huang XY, Yue Z. 2007. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 103:238247.
  • Li Y, Tomiyama H, Sato K, Hatano Y, Yoshino H, Atsumi M, Kitaguchi M, Sasaki S, Kawaguchi S, Miyajima H, Toda T, Mizuno Y, Hattori N. 2005b. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. Neurology 64:19551957.
  • Limousin N, Konofal E, Karroum E, Lohmann E, Theodorou I, Durr A, Arnulf I. 2009. Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations. Mov Disord 24:19701976.
  • Liu S, Ninan I, Antonova I, Battaglia F, Trinchese F, Narasanna A, Kolodilov N, Dauer W, Hawkins RD, Arancio O. 2004. alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J 23:45064516.
  • Liu W, Vives-Bauza C, Acin P, Yamamoto A, Tan Y, Li Y, Magrane J, Stavarache MA, Shaffer S, Chang S, Kaplitt MG, Huang XY, Beal MF, Manfredi G, Li C. 2009. PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. PLoS ONE 4:e4597.
  • Lucking CB, Abbas N, Durr A, Bonifati V, Bonnet AM, de BT, De MG, Wood NW, Agid Y, Brice A. 1998. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group. Lancet 352:13551356.
  • Lucking CB, Durr A, Bonifati V, Vaughan J, De MG, Gasser T, Harhangi BS, Meco G, Denefle P, Wood NW, Agid Y, Brice A. 2000. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 342:15601567.
  • Macedo MG, Verbaan D, Fang Y, van Rooden SM, Visser M, Anar B, Uras A, Groen JL, Rizzu P, van Hilten JJ, Heutink P. 2009. Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. Mov Disord 24:196203.
  • Madegowda RH, Kishore A, Anand A. 2005. Mutational screening of the parkin gene among South Indians with early onset Parkinson's disease. J Neurol Neurosurg Psychiatry 76:15881590.
  • Maraganore DM, de AM, Elbaz A, Farrer MJ, Ioannidis JP, Kruger R, Rocca WA, Schneider NK, Lesnick TG, Lincoln SJ, Hulihan MM, Aasly JO. 2006. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296:661670.
  • Marongiu R, Brancati F, Antonini A, Ialongo T, Ceccarini C, Scarciolla O, Capalbo A, Benti R, Pezzoli G, Dallapiccola B, Goldwurm S, Valente EM. 2007. Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. Hum Mutat 28:98.
  • Marongiu R, Ferraris A, Ialongo T, Michiorri S, Soleti F, Ferrari F, Elia AE, Ghezzi D. 2008. PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. Hum Mutat 29:565.
  • Marras C, Klein C, Lang AE, Wakutani Y, Moreno D, Sato C, Yip E, Munhoz RP, Lohmann K, Djarmati A, Bi A, Rogaeva E. 2010. LRRK2 and Parkin mutations in a family with parkinsonism—Lack of genotype–phenotype correlation. Neurobiol Aging 31:721722.
  • Maruyama M, Ikeuchi T, Saito M, Ishikawa A, Yuasa T, Tanaka H, Hayashi S, Wakabayashi K, Takahashi H, Tsuji S. 2000. Novel mutations, pseudo-dominant inheritance, and possible familial affects in patients with autosomal recessive juvenile parkinsonism. Ann Neurol 48:245250.
  • Mata IF, Alvarez V, Coto E, Blazquez M, Guisasola LM, Salvador C, Kachergus JM, Lincoln SJ, Farrer M. 2005a. Homozygous partial genomic triplication of the parkin gene in early-onset parkinsonism. Neurosci Lett 380:257259.
  • Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS, Lahoz C, Wszolek ZK, Farrer MJ. 2005b. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6:171177.
  • Mata IF, Taylor JP, Kachergus J, Hulihan M, Huerta C, Lahoz C, Blazquez M, Guisasola LM, Salvador C, Ribacoba R, Martinez C, Farrer M, Alvarez V. 2005c. LRRK2 R1441G in Spanish patients with Parkinson's disease. Neurosci Lett 382:309311.
  • Meeus B, Theuns J, Van Broeckhoven C. 2010. GIGYF2 in Parkinson's disease: innocent until proven otherwise. Neurobiol Aging (in press).
  • Mellick GD, Siebert GA, Funayama M, Buchanan DD, Li Y, Imamichi Y, Yoshino H, Silburn PA, Hattori N. 2009. Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. Parkinsonism Relat Disord 15:105109.
  • Michell AW, Barker RA, Raha SK, Raha-Chowdhury R. 2005. A case of late onset sporadic Parkinson's disease with an A53T mutation in alpha-synuclein. J Neurol Neurosurg Psychiatry 76:596597.
  • Mitsumoto A, Nakagawa Y. 2001. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res 35:885893.
  • Mizuta I, Satake W, Nakabayashi Y, Ito C, Suzuki S, Momose Y, Nagai Y, Oka A, Inoko H, Fukae J, Saito Y, Sawabe M, Murayama S, Yamamoto M, Hattori N, Murata M, Toda T. 2006. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet 15:11511158.
  • Moore DJ, Zhang L, Dawson TM, Dawson VL. 2003. A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. J Neurochem 87:15581567.
  • Moro E, Volkmann J, Konig IR, Winkler S, Hiller A, Hassin-Baer S, Herzog J, Schnitzler A, Lohmann K, Pinsker MO, Voges J, Djarmatic A, Seibler P, Lozano AM, Rogaeva E, Lang AE, Deuschl G, Klein C. 2008. Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. Neurology 70:11861191.
  • Mueller JC, Fuchs J, Hofer A, Zimprich A, Lichtner P, Illig T, Berg D, Wullner U, Meitinger T, Gasser T. 2005. Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol 57:535541.
  • Munhoz RP, Sa DS, Rogaeva E, Salehi-Rad S, Sato C, Medeiros H, Farrer M, Lang AE. 2004. Clinical findings in a large family with a parkin ex3delta40 mutation. Arch Neurol 61:701704.
  • Munoz E, Pastor P, Marti MJ, Oliva R, Tolosa E. 2000. A new mutation in the parkin gene in a patient with atypical autosomal recessive juvenile parkinsonism. Neurosci Lett 289:6668.
  • Munoz E, Tolosa E, Pastor P, Marti MJ, Valldeoriola F, Campdelacreu J, Oliva R. 2002. Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism. J Neurol Neurosurg Psychiatry 73:582584.
  • Myhre R, Steinkjer S, Stormyr A, Nilsen GL, Abu ZH, Horany K, Nusier MK, Klungland H. 2008a. Significance of the parkin and PINK1 gene in Jordanian families with incidences of young-onset and juvenile parkinsonism. BMC Neurol 8:47.
  • Myhre R, Toft M, Kachergus J, Hulihan MM, Aasly JO, Klungland H, Farrer MJ. 2008b. Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population. Acta Neurol Scand 118:320327.
  • Narendra D, Tanaka A, Suen DF, Youle RJ. 2008. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183:795803.
  • Narendra D, Tanaka A, Suen DF, Youle RJ. 2009. Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy 5:706708.
  • Nichols WC, Elsaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T. 2007. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology 69:17371744.
  • Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T. 2005. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365:410412.
  • Nichols WC, Pankratz N, Uniacke SK, Pauciulo MW, Halter C, Rudolph A, Conneally PM, Foroud T. 2002. Linkage stratification and mutation analysis at the Parkin locus identifies mutation positive Parkinson's disease families. J Med Genet 39:489492.
  • Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, Kitami T, Sato K, Kuroda R, Tomiyama H, Mizoguchi K, Murata M, Toda T, Imoto I, Inazawa J, Mizuno Y, Hattori N. 2006. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol 59:298309.
  • Nishioka K, Ross OA, Ishii K, Kachergus JM, Ishiwata K, Kitagawa M, Kono S, Obi T, Mizoguchi K, Inoue Y, Imai H, Takanashi M, Mizuno Y, Farrer MJ, Hattori N. 2009. Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord 24:18111819.
  • Nisipeanu P, Inzelberg R, Abo MS, Carasso RL, Blumen SC, Zhang J, Matsumine H, Hattori N, Mizuno Y. 2001. Parkin gene causing benign autosomal recessive juvenile parkinsonism. Neurology 56:15731575.
  • Nuytemans K, Meeus B, Crosiers D, Brouwers N, Goossens D, Engelborghs S, Pals P, Pickut B, Van den BM, Corsmit E, Cras P, De Deyn PP, Del-Favero J, Van BC, Theuns J. 2009. Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Hum Mutat 30:10541061.
  • Nuytemans K, Rademakers R, Theuns J, Pals P, Engelborghs S, Pickut B, de PT, Peeters K, Mattheijssens M, Van den BM, Cras P, De Deyn PP, Van BC. 2008. Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients. Eur J Hum Genet 16:471479.
  • Obi T, Nishioka K, Ross OA, Terada T, Yamazaki K, Sugiura A, Takanashi M, Mizoguchi K, Mori H, Mizuno Y, Hattori N. 2008. Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology 70:238241.
  • Okubadejo N, Britton A, Crews C, Akinyemi R, Hardy J, Singleton A, Bras J. 2008. Analysis of Nigerians with apparently sporadic Parkinson disease for mutations in LRRK2, PRKN and ATXN3. PLoS ONE 3:e3421.
  • Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R. 2003. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol 53:624629.
  • Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N. 2007. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology 69:15951602.
  • Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB. 2006. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354:424425.
  • Paisan-Ruiz C. 2009. LRRK2 gene variation and its contribution to Parkinson disease. Hum Mutat 30:11531160.
  • Paisan-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, Hardy J, Houlden H, Singleton A, Schneider SA. 2009. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 65:1923.
  • Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der BM, Lopez de MA, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de SR, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB. 2004. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595600.
  • Paisan-Ruiz C, Lang AE, Kawarai T, Sato C, Salehi-Rad S, Fisman GK, Al-Khairallah T, St George-Hyslop P, Singleton A, Rogaeva E. 2005. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology 65:696700.
  • Paisan-Ruiz C, Nath P, Washecka N, Gibbs JR, Singleton AB. 2008. Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. Hum Mutat 29:485490.
  • Pals P, Lincoln S, Manning J, Heckman M, Skipper L, Hulihan M, Van den Broeck M, De Pooter T, Cras P, Crook J, Van Broeckhoven C, Farrer MJ. 2004a. alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann Neurol 56:591595.
  • Pals P, Lincoln S, Manning J, Heckman M, Skipper L, Hulihan M, Van den BM, de Pooter T, Cras P, Crook J, Van BC, Farrer MJ. 2004b. alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann Neurol 56:591595.
  • Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, Nichols WC. 2006a. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease. Mov Disord 21:22572260.
  • Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Wojcieszek J, Rudolph A, Shults CW, Foroud T, Nichols WC. 2006b. Mutations in DJ-1 are rare in familial Parkinson disease. Neurosci Lett 408:209213.
  • Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, Doheny KF, Gusella JF, Nichols WC, Foroud T, Myers RH. 2009. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 124:593605.
  • Papadimitriou A, Veletza V, Hadjigeorgiou GM, Patrikiou A, Hirano M, Anastasopoulos I. 1999. Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology 52:651654.
  • Papapetropoulos S, Ellul J, Paschalis C, Athanassiadou A, Papadimitriou A, Papapetropoulos T. 2003. Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece. Eur J Neurol 10:281286.
  • Papapetropoulos S, Paschalis C, Athanassiadou A, Papadimitriou A, Ellul J, Polymeropoulos MH, Papapetropoulos T. 2001. Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. J Neurol Neurosurg Psychiatry 70:662665.
  • Papapetropoulos S, Singer C, Ross OA, Toft M, Johnson JL, Farrer MJ, Mash DC. 2006. Clinical heterogeneity of the LRRK2 G2019S mutation. Arch Neurol 63:12421246.
  • Park J, Lee G, Chung J. 2009. The PINK1-Parkin pathway is involved in the regulation of mitochondrial remodeling process. Biochem Biophys Res Commun 378:518523.
  • Parsian AJ, Racette BA, Zhao JH, Sinha R, Patra B, Perlmutter JS, Parsian A. 2007. Association of alpha-synuclein gene haplotypes with Parkinson's disease. Parkinsonism Relat Disord 13:343347.
  • Pchelina SN, Yakimovskii AF, Emelyanov AK, Ivanova ON, Schwarzman AL, Singleton AB. 2008. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant. Eur J Neurol 15:692696.
  • Pellecchia MT, Varrone A, Annesi G, Amboni M, Cicarelli G, Sansone V, Annesi F, Rocca FE, Vitale C, Pappata S, Quattrone A, Barone P. 2007. Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: an FP-CIT SPECT study. Mov Disord 22:559563.
  • Periquet M, Latouche M, Lohmann E, Rawal N, De MG, Ricard S, Teive H, Fraix V, Vidailhet M, Nicholl D, Barone P, Wood NW, Raskin S, Deleuze JF, Agid Y, Durr A, Brice A. 2003. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain 126:12711278.
  • Periquet M, Lucking C, Vaughan J, Bonifati V, Durr A, De MG, Horstink M, Farrer M, Illarioshkin SN, Pollak P, Borg M, Brefel-Courbon C, Denefle P, Meco G, Gasser T, Breteler MM, Wood N, Agid Y, Brice A. 2001. Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects. Am J Hum Genet 68:617626.
  • Perry G, Zhu X, Babar AK, Siedlak SL, Yang Q, Ito G, Iwatsubo T, Smith MA, Chen SG. 2008. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies. Neurodegener Dis 5:222224.
  • Pesah Y, Pham T, Burgess H, Middlebrooks B, Verstreken P, Zhou Y, Harding M, Bellen H, Mardon G. 2004. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131:21832194.
  • Pigullo S, De LA, Barone P, Marchese R, Bellone E, Colosimo A, Scaglione C, Martinelli P, Di ME, Pizzuti A, Abbruzzese G, Dallapiccola B, Ajmar F, Mandich P. 2004. Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor. Parkinsonism Relat Disord 10:357362.
  • Pineda-Trujillo N, Carvajal-Carmona LG, Buritica O, Moreno S, Uribe C, Pineda D, Toro M, Garcia F, Arias W, Bedoya G, Lopera F, Ruiz-Linares A. 2001. A novel Cys212Tyr founder mutation in parkin and allelic heterogeneity of juvenile Parkinsonism in a population from North West Colombia. Neurosci Lett 298:8790.
  • Plun-Favreau H, Klupsch K, Moisoi N, Gandhi S, Kjaer S, Frith D, Harvey K, Deas E, Harvey RJ, McDonald N, Wood NW, Martins LM, Downward J. 2007. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol 9:12431252.
  • Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di IG, Sanges G, Stenroos ES, Pho LT, Schaffer AA, Lazzarini AM, Nussbaum RL, Duvoisin RC. 1996. Mapping of a gene for Parkinson's disease to chromosome 4q21–q23. Science 274:11971199.
  • Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di IG, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:20452047.
  • Poole AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ, Pallanck LJ. 2008. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 105:16381643.
  • Poorkaj P, Nutt JG, James D, Gancher S, Bird TD, Steinbart E, Schellenberg GD, Payami H. 2004. parkin mutation analysis in clinic patients with early-onset Parkinson [corrected] disease. Am J Med Genet A 129A:4450.
  • Pramstaller PP, Schlossmacher MG, Jacques TS, Scaravilli F, Eskelson C, Pepivani I, Hedrich K, Adel S, Gonzales-McNeal M, Hilker R, Kramer PL, Klein C. 2005. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 58:411422.
  • Prestel J, Gempel K, Hauser TK, Schweitzer K, Prokisch H, Ahting U, Freudenstein D, Bueltmann E, Naegele T, Berg D, Klopstock T, Gasser T. 2008. Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation. J Neurol 255:643648.
  • Pridgeon JW, Olzmann JA, Chin LS, Li L. 2007. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 5:e172.
  • Puschmann A, Ross OA, Vilarino-Guell C, Lincoln SJ, Kachergus JM, Cobb SA, Lindquist SG, Nielsen JE, Wszolek ZK, Farrer M, Widner H, van WD, Hagerstrom D, Markopoulou K, Chase BA, Nilsson K, Reimer J, Nilsson C. 2009. A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat Disord 15:627632.
  • Rajput A, Dickson DW, Robinson CA, Ross OA, Dachsel JC, Lincoln SJ, Cobb SA, Rajput ML, Farrer MJ. 2006. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67:15061508.
  • Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI, Kubisch C. 2006. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38:11841191.
  • Ramsey CP, Giasson BI. 2008. The E163K DJ-1 mutant shows specific antioxidant deficiency. Brain Res 1239:111.
  • Rawal N, Periquet M, Lohmann E, Lucking CB, Teive HA, Ambrosio G, Raskin S, Lincoln S, Hattori N, Guimaraes J, Horstink MW, Dos Santos BW, Brousolle E, Destee A, Mizuno Y, Farrer M, Deleuze JF, De MG, Agid Y, Durr A, Brice A. 2003. New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism. Neurology 60:13781381.
  • Reetz K, Lencer R, Steinlechner S, Gaser C, Hagenah J, Buchel C, Petersen D, Kock N, Djarmati A, Siebner HR, Klein C, Binkofski F. 2008. Limbic and frontal cortical degeneration is associated with psychiatric symptoms in PINK1 mutation carriers. Biol Psychiatry 64:241247.
  • Rocca FE, Annesi F, Ciro CI, Carrideo S, Tarantino P, Provenzano G, Civitelli D, De Marco EV, Quattrone A, Annesi G. 2007. Novel human pathological mutations. Gene symbol: PARK2. Disease: Parkinson's disease. Hum Genet 122:415.
  • Rogaeva E, Johnson J, Lang AE, Gulick C, Gwinn-Hardy K, Kawarai T, Sato C, Morgan A, Werner J, Nussbaum R, Petit A, Okun MS, McInerney A, Mandel R, Groen JL, Fernandez HH, Postuma R, Foote KD, Salehi-Rad S, Liang Y, Reimsnider S, Tandon A, Hardy J, St George-Hyslop P, Singleton AB. 2004. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 61:18981904.
  • Rohe CF, Montagna P, Breedveld G, Cortelli P, Oostra BA, Bonifati V. 2004. Homozygous PINK1 C-terminus mutation causing early-onset parkinsonism. Ann Neurol 56:427431.
  • Romito LM, Contarino MF, Ghezzi D, Franzini A, Garavaglia B, Albanese A. 2005. High frequency stimulation of the subthalamic nucleus is efficacious in Parkin disease. J Neurol 252:208211.
  • Ross OA, Gosal D, Stone JT, Lincoln SJ, Heckman MG, Irvine GB, Johnston JA, Gibson JM, Farrer MJ, Lynch T. 2007. Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease. Mech Ageing Dev 128:378382.
  • Ross OA, Wu YR, Lee MC, Funayama M, Chen ML, Soto AI, Mata IF, Lee-Chen GJ, Chen CM, Tang M, Zhao Y, Hattori N, Farrer MJ, Tan EK, Wu RM. 2008. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol 64:8892.
  • Samaranch L, Lorenzo-Betancor O, Arbelo JM, Ferrer I, Lorenzo E, Irigoyen J, Pastor MA, Marrero C, Isla C, Herrera-Henriquez J, Pastor P. 2010. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 133:11281142.
  • Sanchez MP, Gonzalo I, Avila J, de Yebenes JG. 2002. Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation. J Alzheimers Dis 4:399404.
  • Santos-Reboucas CB, Abdalla CB, Baldi FJ, Martins PA, Correa JC, Goncalves AP, Cunha MS, Borges MB, Pereira JS, Laks J, Pimentel MM. 2008. Co-occurrence of sporadic parkinsonism and late-onset Alzheimer's disease in a Brazilian male with the LRRK2 p.G2019S mutation. Genet Test 12:471473.
  • Sasaki S, Shirata A, Yamane K, Iwata M. 2004. Parkin-positive autosomal recessive juvenile Parkinsonism with alpha-synuclein-positive inclusions. Neurology 63:678682.
  • Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T. 2009. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41:13031307.
  • Savettieri G, Annesi G, Civitelli D, Ciro CI, Salemi G, Ragonese P, Annesi F, Tarantino P, Terruso V, D'Amelio M, Quattrone A. 2008. Identification of the novel D297fsX318 PINK1 mutation and phenotype variation in a family with early-onset Parkinson's disease. Parkinsonism Relat Disord 14:509512.
  • Scherfler C, Khan NL, Pavese N, Eunson L, Graham E, Lees AJ, Quinn NP, Wood NW, Brooks DJ, Piccini PP. 2004. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain 127:13321342.
  • Schlitter AM, Woitalla D, Mueller T, Epplen JT, Dekomien G. 2006. The LRRK2 gene in Parkinson's disease: mutation screening in patients from Germany. J Neurol Neurosurg Psychiatry 77:891892.
  • Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T. 2000. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25:302305.
  • Shyu WC, Lin SZ, Chiang MF, Pang CY, Chen SY, Hsin YL, Thajeb P, Lee YJ, Li H. 2005. Early-onset Parkinson's disease in a Chinese population: 99mTc-TRODAT-1 SPECT, Parkin gene analysis and clinical study. Parkinsonism Relat Disord 11:173180.
  • Sim CH, Lio DS, Mok SS, Masters CL, Hill AF, Culvenor JG, Cheng HC. 2006. C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet 15:32513262.
  • Simon-Sanchez J, Marti-Masso JF, Sanchez-Mut JV, Paisan-Ruiz C, Martinez-Gil A, Ruiz-Martinez J, Saenz A, Singleton AB, Lopez de MA, Perez-Tur J. 2006. Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. Mov Disord 21:19541959.
  • Simon-Sanchez J, Scholz S, Matarin MM, Fung HC, Hernandez D, Gibbs JR, Britton A, Hardy J, Singleton A. 2008. Genomewide SNP assay reveals mutations underlying Parkinson disease. Hum Mutat 29:315322.
  • Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P. 2009. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41:13081312.
  • Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J. 2003. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302:841.
  • Sironi F, Primignani P, Zini M, Tunesi S, Ruffmann C, Ricca S, Brambilla T. 2008. Parkin analysis in early onset Parkinson's disease. Parkinsonism Relat Disord 14:326333.
  • Skipper L, Shen H, Chua E, Bonnard C, Kolatkar P, Tan LC, Jamora RD, Puvan K, Puong KY, Zhao Y, Pavanni R, Wong MC, Yuen Y, Farrer M, Liu JJ, Tan EK. 2005. Analysis of LRRK2 functional domains in nondominant Parkinson disease. Neurology 65:13191321.
  • Spanaki C, Latsoudis H, Plaitakis A. 2006. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology 67:15181519.
  • Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. 1998. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 95:64696473.
  • Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA. 2001. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol 49:313319.
  • Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D, Gasser T, Wszolek Z, Muller T, Bornemann A, Wolburg H, Downward J, Riess O, Schulz JB, Kruger R. 2005. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 14:20992111.
  • Sun M, Latourelle JC, Wooten GF, Lew MF, Klein C, Shill HA, Golbe LI, Mark MH. 2006. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol 63:826832.
  • Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. 2004. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 5:213218.
  • Tan EK, Chai A, Teo YY, Zhao Y, Tan C, Shen H, Chandran VR, Teoh ML, Yih Y, Pavanni R, Wong MC, Puvan K, Lo YL, Yap E. 2004. Alpha-synuclein haplotypes implicated in risk of Parkinson's disease. Neurology 62:128131.
  • Tan EK, Peng R, Wu YR, Wu RM, Wu-Chou YH, Tan LC, An XK, Chen CM, Fook-Chong S, Lu CS. 2009. LRRK2 G2385R modulates age at onset in Parkinson's disease: a multi-center pooled analysis. Am J Med Genet B Neuropsychiatr Genet 150B:10221023.
  • Tan EK, Skipper L, Chua E, Wong MC, Pavanni R, Bonnard C, Kolatkar P, Liu JJ. 2006a. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease. Mov Disord 21:9971001.
  • Tan EK, Tan LC, Lim HQ, Li R, Tang M, Yih Y, Pavanni R, Prakash KM, Fook-Chong S, Zhao Y. 2008. LRRK2 R1628P increases risk of Parkinson's disease: replication evidence. Hum Genet 124:287288.
  • Tan EK, Yew K, Chua E, Puvan K, Shen H, Lee E, Puong KY, Zhao Y, Pavanni R, Wong MC, Jamora D, de SD, Moe KT, Woon FP, Yuen Y, Tan L. 2006b. PINK1 mutations in sporadic early-onset Parkinson's disease. Mov Disord 21:789793.
  • Tan EK, Yew K, Chua E, Shen H, Jamora RD, Lee E, Puong KY, Zhao Y, Pavanni R, Wong MC, Puvan K, Yih Y, Tan LC. 2005. Analysis of PINK1 in Asian patients with familial parkinsonism. Clin Genet 68:468470.
  • Tan EK, Zhao Y, Skipper L, Tan MG, Di FA, Sun L, Fook-Chong S, Tang S, Chua E, Yuen Y, Tan L, Pavanni R, Wong MC, Kolatkar P, Lu CS, Bonifati V, Liu JJ. 2007. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet 120:857863.
  • Tan LC, Tanner CM, Chen R, Chan P, Farrer M, Hardy J, Langston JW. 2003. Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation. Mov Disord 18:758763.
  • Tang B, Xiong H, Sun P, Zhang Y, Wang D, Hu Z, Zhu Z, Ma H, Pan Q, Xia JH, Xia K, Zhang Z. 2006. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum Mol Genet 15:18161825.
  • Tarantino P, Ciro CI, Annesi F, Rocca FE, Carrideo S, Provenzano G, Civitelli D, De Marco EV, Quattrone A, Annesi G. 2007. Novel human pathological mutations. Gene symbol: PARK2. Disease: Parkinson's disease. Hum Genet 122:415.
  • Tarantino P, Civitelli D, Annesi F, De Marco EV, Rocca FE, Pugliese P, Nicoletti G, Carrideo S, Provenzano G, Annesi G, Quattrone A. 2009. Compound heterozygosity in DJ-1 gene non-coding portion related to parkinsonism. Parkinsonism Relat Disord 15:324326.
  • Terreni L, Calabrese E, Calella AM, Forloni G, Mariani C. 2001. New mutation (R42P) of the parkin gene in the ubiquitinlike domain associated with parkinsonism. Neurology 56:463466.
  • Toft M, Myhre R, Pielsticker L, White LR, Aasly JO, Farrer MJ. 2007. PINK1 mutation heterozygosity and the risk of Parkinson's disease. J Neurol Neurosurg Psychiatry 78:8284.
  • Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, Kubo S, Sato K, Hattori T. 2006. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord 21:11021108.
  • Tomiyama H, Mizuta I, Li Y, Funayama M, Yoshino H, Li L, Murata M, Yamamoto M, Kubo S, Mizuno Y, Toda T, Hattori N. 2008. LRRK2 P755L variant in sporadic Parkinson's disease. J Hum Genet 53:10121015.
  • Uversky VN, Lee HJ, Li J, Fink AL, Lee SJ. 2001a. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem 276:4349543498.
  • Uversky VN, Li J, Fink AL. 2001b. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 276:1073710744.
  • Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, Albanese A, Wood NW. 2001. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 68:895900.
  • Valente EM, bou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del TD, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW. 2004a. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304:11581160.
  • Valente EM, Brancati F, Ferraris A, Graham EA, Davis MB, Breteler MM, Gasser T. 2002. PARK6-linked parkinsonism occurs in several European families. Ann Neurol 51:1418.
  • Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, Caputo V, Romito L, Albanese A, Dallapiccola B, Bentivoglio AR. 2004b. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 56:336341.
  • van Duijn CM, Dekker MC, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, Snijders PJ, Testers L, Breedveld GJ, Horstink M, Sandkuijl LA, van Swieten JC, Oostra BA, Heutink P. 2001. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 69:629634.
  • Varrone A, Pellecchia MT, Amboni M, Sansone V, Salvatore E, Ghezzi D, Garavaglia B, Brice A, Brunetti A, Bonavita V, De MG, Salvatore M, Pappata S, Barone P. 2004. Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease. Neurology 63:20972103.
  • Wakabayashi K, Hayashi S, Ishikawa A, Hayashi T, Okuizumi K, Tanaka H, Tsuji S, Takahashi H. 1998. Autosomal dominant diffuse Lewy body disease. Acta Neuropathol 96:207210.
  • Wang HL, Chou AH, Yeh TH, Li AH, Chen YL, Kuo YL, Tsai SR, Yu ST. 2007. PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiol Dis 28:216226.
  • Wang M, Hattori N, Matsumine H, Kobayashi T, Yoshino H, Morioka A, Kitada T, Asakawa S, Minoshima S, Shimizu N, Mizuno Y. 1999. Polymorphism in the parkin gene in sporadic Parkinson's disease. Ann Neurol 45:655658.
  • Wang X, Schwarz TL. 2009. The mechanism of Ca2+-dependent regulation of kinesin-mediated mitochondrial motility. Cell 136:163174.
  • Wang Y, Clark LN, Louis ED, Mejia-Santana H, Harris J, Cote LJ, Waters C, Andrews H, Ford B, Frucht S, Fahn S, Ottman R, Rabinowitz D, Marder K. 2008. Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort method. Arch Neurol 65:467474.
  • Waters CH, Miller CA. 1994. Autosomal dominant Lewy body parkinsonism in a four-generation family. Ann Neurol 35:5964.
  • Weihofen A, Thomas KJ, Ostaszewski BL, Cookson MR, Selkoe DJ. 2009. Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry 48:20452052.
  • Weng YH, Chou YH, Wu WS, Lin KJ, Chang HC, Yen TC, Chen RS, Wey SP, Lu CS. 2007. PINK1 mutation in Taiwanese early-onset parkinsonism: clinical, genetic, and dopamine transporter studies. J Neurol 254:13471355.
  • West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM. 2005. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102:1684216847.
  • West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM. 2007. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16:223232.
  • Winkler S, Hagenah J, Lincoln S, Heckman M, Haugarvoll K, Lohmann-Hedrich K, Kostic V, Farrer M, Klein C. 2007. alpha-Synuclein and Parkinson disease susceptibility. Neurology 69:17451750.
  • Wu RM, Bounds R, Lincoln S, Hulihan M, Lin CH, Hwu WL, Chen J, Gwinn-Hardy K, Farrer M. 2005. Parkin mutations and early-onset parkinsonism in a Taiwanese cohort. Arch Neurol 62:8287.
  • Xiong H, Wang D, Chen L, Choo YS, Ma H, Tang C, Xia K, Jiang W, Ronai Z, Zhuang X, Zhang Z. 2009. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 119:650660.
  • Xiromerisiou G, Hadjigeorgiou GM, Gourbali V, Johnson J, Papakonstantinou I, Papadimitriou A, Singleton AB. 2007. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants. Eur J Neurol 14:711.
  • Xu Y, Liu Z, Wang Y, Tao E, Chen G, Chen B. 2002. [A new point mutation on exon 2 of parkin gene in Parkinson's disease]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 19:409411.
  • Zabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, Yearout D, Raskind WH, Griffith A. 2005. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65:741744.
  • Zabetian CP, Yamamoto M, Lopez AN, Ujike H, Mata IF, Izumi Y, Kaji R, Maruyama H, Morino H, Oda M, Hutter CM, Edwards KL, Schellenberg GD, Tsuang DW, Yearout D, Larson EB, Kawakami H. 2009. LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease. Mov Disord 24:10341041.
  • Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez TE, del ST, Munoz DG, de Yebenes JG. 2004. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164173.
  • Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. 2000. Parkin functions as an E2-dependent ubiquitin–protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 97:1335413359.
  • Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. 2004a. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601607.
  • Zimprich A, Muller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M, Lockhart P. 2004b. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 74:1119.